A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Novartis
Rutgers, The State University of New Jersey
University of Pittsburgh
Jazz Pharmaceuticals
University of Florida
Cornerstone Pharmaceuticals
Mayo Clinic
Enzon Pharmaceuticals, Inc.
M.D. Anderson Cancer Center